

Cover Story
Capitol HillFree
By Matthew Bin Han Ong
After taking eight months to respond to a House committee’s questions about policies on handling of sexual misconduct cases, a letter from NIH has provided answers that critics describe as vague and inadequate.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Alec Kimmelman named director of Perlmutter Cancer Center, quickly replacing ousted Benjamin Neel
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State